Does BPC 157 Cause Cancer?

Your body already has a system for growing new blood vessels, and it runs on chemical signals the same way a radio tower broadcasts to receivers. The signal is called VEGF, which stands for vascular endothelial growth factor, and the receiver is a protein on the surface of your cells called VEGFR2. When tissue gets damaged and needs repair, your body sends out VEGF signals, those signals bind to VEGFR2 receptors, and the cells respond by building new blood vessels toward the damaged area. That's the whole mechanism in one sentence.

BPC-157 works by turning up the volume on that receiver. Specifically, it works through something called VEGFR2 upregulation, which means it increases the number of VEGFR2 receptors sitting on the surface of your cells so those cells become more sensitive to the VEGF signal that's already circulating. A 2017 study using a rat hind limb ischemia model showed that BPC-157 activated the VEGFR2-Akt-eNOS signaling pathway and measurably increased vessel density in ischemic tissue. More receptors means the same signal produces a stronger response, which is why the healing and recovery effects people report seem real and why the research on tissue repair is actually fairly consistent.

Now here is where the cancer question enters.

Tumors use the exact same pathway. When a small cluster of cancerous cells reaches a size where it can no longer get enough oxygen and nutrients by diffusion alone, it starts sending out VEGF signals of its own to recruit blood vessel growth toward itself. This process is called angiogenesis, which is the formation of new blood vessels, and it is what allows a tumor to grow from a microscopic cluster into something that can spread and cause serious damage. The reason some cancer drugs work is that they block VEGF or VEGFR2 directly, cutting off that blood supply and essentially starving the tumor. The logic there is straightforward: no vessels, no growth.

So if BPC-157 increases VEGFR2 sensitivity across your cells, the concern is not that it creates cancer but that it could accelerate the growth of a tumor that is already there, one you may not know exists yet because it has not been detected.

That concern is mechanistically sound. It is based on real biology. But a theoretical mechanism and a demonstrated effect are not the same thing, and that distinction matters a lot here.

There is one study that actually tested BPC-157 against cancer cells directly. It was a 2004 conference abstract by researchers in the Sikiric group, testing BPC-157 on SK-Mel-1 human melanoma cells in a lab dish at concentrations of 2 nanograms and 10 nanograms. The result was that BPC-157 lowered the total S-phase fraction, which is the portion of cells actively dividing, by up to 55 percent compared to controls. That sounds reassuring. A reduction in cancer cell division is the opposite of what the theoretical concern predicts.

But there are several things you need to know before you take that result at face value.

It is a single study, in a single cell line, conducted in a dish, by a research group that has a clear interest in BPC-157 research, and it has never been independently replicated in over twenty years. A 2025 published commentary confirmed this directly: no published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study is still sitting alone with no follow-up from anyone else.

In vitro results and in vivo results are fundamentally different things. A cell in a dish does not have a blood supply, an immune system, neighboring tissues, or the mechanical and chemical environment of a living organism. The fact that BPC-157 appeared to suppress cell division in an isolated melanoma cell line does not tell us what happens when a person with a growing tumor introduces a compound that upregulates angiogenic signaling systemically.

There is also a second mechanistic concern that goes beyond VEGF. BPC-157 activates something called FAK-paxillin signaling, which is a pathway involved in how cells adhere to surfaces and migrate through tissue. That pathway is a known contributor to cancer cell invasion, which is the process where cancer cells break away from the original tumor and move into surrounding tissue or the bloodstream. This does not prove BPC-157 promotes invasion. It means there is another biological mechanism that warrants study before we can say we understand the risk profile clearly.

So where does that leave the actual question of whether BPC-157 causes cancer?

There is no evidence it initiates cancer. There is no evidence it has caused cancer in any study, in any animal, or in any reported human case. What exists is a plausible mechanism by which it could theoretically accelerate a tumor that is already present, one piece of in vitro data suggesting the opposite effect in one cell type, and no in vivo tumor studies at all. A 2025 narrative review put it plainly: BPC-157 should be considered investigational until well-designed human trials are conducted.

For someone with no cancer history and no known risk factors, the theoretical risk appears low based on current evidence, though low is not the same as zero and no one has studied this directly in humans.

For someone with active cancer, a history of cancer, or precancerous conditions, the gap in the evidence is not a reason for comfort. It is a reason to wait. Avoid BPC-157 until studies in living organisms actually test what happens to tumors when this compound is present.

The broader point is this: a compound that heals tissue by amplifying your body's repair signals is not doing something separate from cancer biology. It is operating inside the same system that cancers hijack. That does not make it dangerous by default, but it means the safety question cannot be answered by injury healing studies alone. You need tumor data to answer a tumor question, and that data does not exist yet.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness